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expectancy and QALYs compared to CPI/r + OB with an incre-
mental cost per additional year of life gained of $51,058 and
the incremental cost per QALY of $52,517.
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OBJECTIVE: Invasive fungal infections (IFIs) have emerged as
the major infection-related cause of morbidity and mortality in
patients undergoing transplantations. A recent RCT in allogeneic
hematopoietic stem cell transplantation (HSCT) recipients with
grade 2–4 or extensive chronic graft-versus-host disease com-
pared the efﬁcacy of posaconazole and ﬂuconazole in the preven-
tion of IFIs. At the end of the ﬁxed 112-day treatment period,
posaconazole was as effective as ﬂuconazole in preventing IFIs
(5% vs. 9%); signiﬁcantly reduced breakthrough Aspergillus
infections (2% vs. 7%, p = 0.0059); and decreased IFI-related
mortality (1% vs. 4%; p = 0.0413). We evaluated posaconazole
cost-effectiveness from the Canadian health care system perspec-
tive. METHODS: A trial-based decision-analytic model was
developed. The probabilities of experiencing an IFI, IFI-related
death, and death from other causes over 112 days post treatment
were estimated. To extrapolate results beyond the trial, the model
was extended to a lifetime horizon using 1-month Markov cycles
in which mortality rate was speciﬁc to the underlying disease
obtained from clinical data. Pharmacotherapy and IFI-related
costs were estimated using published literature. The model was
used to estimate costs, life-years saved (LYS), and the incremental
cost-effectiveness ratio (ICER) of posaconazole vs. ﬂuconazole
(2007 CND$). RESULTS: Posaconazole appeared to be more
effective with increased LYS (7.95 vs. 7.81) however, more costly
($16,784 vs. $11,760) than the alternative over a lifetime
horizon. The ICER of posaconazole was $34,668/LYS compared
to ﬂuconazole. A second-order probabilistic Monte Carlo sensi-
tivity analysis was conducted to assess the effects of parameter
uncertainty, particularly concerning treatment efﬁcacy and costs
of IFIs. There was a 4% probability that posaconazole was both
more effective and less costly than Fluconazole, and a 66%
probability that posaconazole ICER was at or below the
$50,000/LYS threshold. CONCLUSION: In addition to the
proven efﬁcacy, posaconazole appeared to be cost-effective rela-
tive to ﬂuconazole in the prophylaxis of IFIs among patients
undergoing allogeneic HSCT.
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OBJECTIVE: To evaluate the cost-effectiveness of vancomycin
versus linezolid in complicated skin and soft tissue infections
(cSSTIs) with methicillin-resistant Staphylococcus aureus
(MRSA) using a decision analytic (DA) model. METHODS: A
decision model was created to evaluate the cost-effectiveness of
vancomycin and linezolid in the treatment of MRSA cSSTIs.
Outcome probabilities were determined from published clinical
trials. The main dependent variables of interest were: total
direct costs, cost-effectiveness ratios (CER), and incremental
cost-effectiveness ratio (ICER). Univariate (one-way) sensitivity
analyses were conducted for all probabilities and costs used in
the model. Second-order Monte Carlo simulation (probabilistic
sensitivity analysis) using 10,000 samples was also performed
to test for robustness, and an acceptability curve was plotted
along a willingness to pay axis. RESULTS: The DA model pre-
dicted that linezolid was the most cost-effective strategy from
the base-case analysis. Average CER for linezolid and vanco-
mycin were 11,089.70 (USD/cure) and 16,299.75 (USD/cure),
respectively. Univariate sensitivity analyses revealed that vanco-
mycin IV duration and linezolid responder probability were
sensitive across the range. Other parameters did not signiﬁ-
cantly change the base-case result. Probabilistic sensitivity
analysis showed that a majority of the points favored linezolid
being dominant over vancomycin. Acceptability curve showed a
95% probability that linezolid was the most cost-effective
strategy with a willingness to pay up to 200,000 (USD)/cure.
CONCLUSION: Based on this decision model, linezolid was
the most cost-effective strategy compared to vancomycin pri-
marily because of shorter IV duration and higher responder
probability.
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OBJECTIVE: Oseltamivir has been shown to reduce the duration
of inﬂuenza symptoms in children, but recent reports of neuro-
psychiatric adverse events deserve consideration. This study
investigated the effect that these adverse events have on the
estimated cost-effectiveness of oseltamivir treatment in children.
METHODS: A decision analytic model was developed to project
the costs and effectiveness of three clinical options for otherwise
healthy ﬁve to eleven year old children with inﬂuenza-like illness:
no antiviral treatment, rapid testing for inﬂuenza and treatment
with oseltamivir if test is positive, and empirical oseltamivir
treatment. The main outcome measure was the incremental cost-
effectiveness ratio (ICER) of each intervention, in dollars per
quality adjusted life year (QALY) gained. Deterministic and
probabilistic sensitivity analyses were performed to quantify
the effects of parameter uncertainty. RESULTS: In the base
case analysis, which assumed neuropsychiatric adverse events
occurred in 0.065% of treated patients, the test and treat
strategy led to an ICER of $30,800 (95% CI: $12,700 to
$207,700) per QALY gained, compared to no antiviral treat-
ment. Empirical treatment was a more costly, but more effective
strategy, with an ICER of $62,500 (95% CI: cost-saving to
$2,138,300) per QALY gained. When the probability of neurop-
sychiatric adverse events was increased to 10 times the baseline
estimate (0.65%), the test and treat strategy led to an ICER of
$32,300/QALY, while empirical treatment was associated with
an ICER of $75,000/QALY. These ratios increased to $53,300
and $410,000, respectively, when this adverse event rate was
raised to 100 times its baseline value (6.5%). CONCLUSION:
Despite recent concern surrounding the risk of neuropsychiatric
adverse events, the use of oseltamivir is projected to remain a
cost-effective treatment option in this pediatric population. This
conclusion is robust to substantial increases in the likelihood of
these events, particularly when oseltamivir is used in conjunction
with rapid testing for inﬂuenza.
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